Page 2 - Chris Senner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -- Conference Call and Webcast Today at 5:00 PM Eastern Time -ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on...

EXEL earnings call for the period ending September 30, 2023.

EXEL earnings call for the period ending June 30, 2023.

Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Secod Quarter 2023 Financial Results Conference Call. My name is Tawanda and I'll be your operator for today.

EXEL earnings call for the period ending March 31, 2023.